Who are Pembrolizumab Formulated with Berahyaluronidase Alfa's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pembrolizumab-formulated-with-berahyaluronidase-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pembrolizumab Formulated with Berahyaluronidase Alfa — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab Formulated with Berahyaluronidase Alfa (Pembrolizumab Formulated with Berahyaluronidase Alfa) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor with recombinant human hyaluronidase. Area: Oncology.

phase 3 PD-1 inhibitor with recombinant human hyaluronidase PD-1; hyaluronic acid (via berahyaluronidase alfa) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Pembrolizumab Formulated with Berahyaluronidase Alfa (Pembrolizumab Formulated with Berahyaluronidase Alfa) — Merck Sharp & Dohme LLC. Pembrolizumab blocks PD-1 on immune cells to restore anti-tumor immunity, while berahyaluronidase alfa enhances subcutaneous drug delivery by temporarily degrading hyaluronic acid in tissue.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pembrolizumab Formulated with Berahyaluronidase Alfa TARGET	Pembrolizumab Formulated with Berahyaluronidase Alfa	Merck Sharp & Dohme LLC	phase 3	PD-1 inhibitor with recombinant human hyaluronidase	PD-1; hyaluronic acid (via berahyaluronidase alfa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor with recombinant human hyaluronidase class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pembrolizumab Formulated with Berahyaluronidase Alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/pembrolizumab-formulated-with-berahyaluronidase-alfa. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab